Evidence map›Paper›PMID 36602041›Full record

ArticleJournal of diabetes science and technology2024

Continuous Glucose Monitoring of Steroid-Induced Hyperglycemia in Patients With Dermatologic Diseases.

Monika Kleinhans, Lea Jessica Albrecht, Sven Benson, Dagmar Fuhrer, Joachim Dissemond, Susanne Tan

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes science and technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07652528 (Steroid-induced Hyperglycemia Management With Insulin Patch Pump in Sudden Sensorineural Hearing Loss), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07652528 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Steroid-induced Hyperglycemia Management With Insulin Patch Pump in Sudden Sensorineural Hearing Loss: a CGM-guided Exploratory Randomized Controlled Trial (SHIP Trial)

TypeinterventionalSponsorHallym UniversityRan2026 to 2028Enrolled50ConditionsSudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 DiabetesArmsCareLevo Patch-type Insulin Pump, Insulin Glargine U-100 (Lantus), Fast-acting Insulin Aspart (Fiasp), CareSens Air Continuous Glucose Monitor
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Glucocorticoid-Induced Hyperglycemia: A Neglected Problem.Endocrinology and metabolism (Seoul, Korea) · 2024
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Monika KleinhansDepartment of Dermatology, Allergology and Venerology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0002-9079-5032
Lea Jessica AlbrechtDepartment of Dermatology, Allergology and Venerology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Sven BensonInstitute of Medical Psychology and Behavioral Immunobiology & Institute for Medical Education, Center for Translational Neuro- and Behavioral Sciences, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Dagmar FuhrerDepartment of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Joachim DissemondDepartment of Dermatology, Allergology and Venerology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Susanne TanDepartment of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0003-2692-8643
University of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesSystemic administration of glucocorticoids is a mainstay therapy for various inflammatory diseases and may lead to hyperglycemia, which carries the risk of worsening preexisting diabetes and triggering steroid-induced diabetes. Therefore, we aimed to identify patients at risk and to quantify severity of steroid-induced hyperglycemia (SIH) by continuous glucose monitoring (CGM) in hospitalized patients needing systemic glucocorticoid treatment. PATIENTS AND

methodsThis prospective study included 51 steroid-naive, dermatological patients requiring systemic high-dose glucocorticoid treatment at the Department of Dermatology of the University Hospital Essen. After careful diabetes-specific assessment at admission, glucose monitoring was performed using a CGM system and glucose profile was analyzed in patients with and without SIH.

resultsSIH occurred in 47.1% of all treated patients, and a relevant part of patients with initial normoglycemia developed SIH (2/10 patients). Doubling of SIH incidence was observed with each severity grade of dysglycemia (4/10 in prediabetes; 9/10 in diabetes). Patients with SIH spend nearly 6 hours daily above targeted glucose range, and severe hyperglycemia was observed for 1.2 hours/day.

conclusionsOur study underlines the need for dedicated glucose monitoring in dermatologic patients on systemic glucocorticoid therapy by demonstrating its impact on glucose metabolism.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringGlucocorticoidsHyperglycemiaSkin DiseasesAdultAgedContinuous Glucose MonitoringFemaleHumansMaleMiddle AgedProspective StudiesBlood GlucoseGlucocorticoidscontinuous glucose monitoringdiabetes mellitusglucocorticoidsteroid-induced diabetessteroid-induced hyperglycemia

Identifiers

PMID36602041
PMCPMC11307234
OpenAlexW4313545586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.